{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:47:27Z","timestamp":1792802847568,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["57440917"],"award-info":[{"award-number":["57440917"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Multiple myeloma (MM) is a devastating disease with low survival rates worldwide. The mean lifetime of patients may be extendable with new drug alternatives. Aurora A kinase (AURKA) is crucial in oncogenesis, because its overexpression or amplification may incline the development of various types of cancer, including MM. Therefore, inhibitors of AURKA are innovative and promising targets. Natural compounds always represented a valuable resource for anticancer drug development. In the present study, based on virtual drug screening of more than 48,000 natural compounds, the antibiotic deschloro-chlorotricin (DCCT) has been identified to bind to AURKA with even higher binding affinity (free bindung energy: \u221212.25\u00a0kcal\/mol) than the known AURKA inhibitor, alisertib (free binding energy: \u221211.25\u00a0kcal\/mol). The in silico studies have been verified in vitro by using microscale thermophoresis. DCCT inhibited MM cell lines (KMS-11, L-363, RPMI-8226, MOLP-8, OPM-2, NCI-H929) with IC<jats:sub>50<\/jats:sub> values in a range from 0.01 to 0.12\u00a0\u03bcM. Furthermore, DCCT downregulated AURKA protein expression, induced G2\/M cell cycle arrest and disturbed the cellular microtubule network as determined by Western blotting, flow cytometry, and fluorescence microscopy. Thus, DCCT may be a promising lead structure for further derivatization and the development of specific AURKA inhibitors in MM therapy.<\/jats:p>","DOI":"10.1007\/s10637-020-01012-2","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:02:50Z","timestamp":1601053370000},"page":"348-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9561-8994","authenticated-orcid":false,"given":"Nadire","family":"\u00d6zenver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-2516","authenticated-orcid":false,"given":"Sara","family":"Abdelfatah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2637-1681","authenticated-orcid":false,"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"issue":"12","key":"1012_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"7","key":"1012_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ajh.24402","volume":"91","author":"RS Vincent","year":"2016","unstructured":"Vincent RS (2016) Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91(7):719\u2013734. https:\/\/doi.org\/10.1002\/ajh.24402","journal-title":"Am J Hematol"},{"issue":"25","key":"1012_CR3","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1182\/blood-2009-12-259523","volume":"115","author":"G G\u00f6rg\u00fcn","year":"2010","unstructured":"G\u00f6rg\u00fcn G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC (2010) A novel Aurora-a kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115(25):5202\u20135213. https:\/\/doi.org\/10.1182\/blood-2009-12-259523","journal-title":"Blood"},{"key":"1012_CR4","unstructured":"National Cancer Institute (2020) Cancer stat facts: myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"1012_CR5","volume-title":"Resistance to targeted ABC transporters in Cancer","author":"T Efferth","year":"2014","unstructured":"Efferth T (2014) Resistance to targeted ABC transporters in Cancer. Springer, New York"},{"key":"1012_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T (2018) Drug resistance in multiple myeloma. Cancer Treat Rev 70:199\u2013208. https:\/\/doi.org\/10.1016\/j.ctrv.2018.09.001","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1012_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.gde.2003.11.006","volume":"14","author":"P Meraldi","year":"2004","unstructured":"Meraldi P, Honda R, Nigg EA (2004) Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 14(1):29\u201336. https:\/\/doi.org\/10.1016\/j.gde.2003.11.006","journal-title":"Curr Opin Genet Dev"},{"key":"1012_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1479-5876-12-200","volume":"12","author":"J Xu","year":"2014","unstructured":"Xu J, Yue CF, Zhou WH, Qian YM, Zhang Y, Wang SW, Liu AW, Liu Q (2014) Aurora-a contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis. J Transl Med 12:200\u2013200. https:\/\/doi.org\/10.1186\/1479-5876-12-200","journal-title":"J Transl Med"},{"issue":"14","key":"1012_CR9","doi-asserted-by":"publisher","first-page":"23937","DOI":"10.18632\/oncotarget.14893","volume":"8","author":"A Tang","year":"2017","unstructured":"Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J (2017) Aurora kinases: novel therapy targets in cancers. Oncotarget 8(14):23937\u201323954. https:\/\/doi.org\/10.18632\/oncotarget.14893","journal-title":"Oncotarget"},{"issue":"12","key":"1012_CR10","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1158\/1078-0432.Ccr-06-2979","volume":"13","author":"RW Wilkinson","year":"2007","unstructured":"Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13(12):3682\u20133688. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-2979","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1012_CR11","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s10637-012-9798-6","volume":"30","author":"M Kollareddy","year":"2012","unstructured":"Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M (2012) Aurora kinase inhibitors: progress towards the clinic. Investig New Drugs 30(6):2411\u20132432. https:\/\/doi.org\/10.1007\/s10637-012-9798-6","journal-title":"Investig New Drugs"},{"issue":"3","key":"1012_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","volume":"79","author":"DJ Newman","year":"2016","unstructured":"Newman DJ, Cragg GM (2016) Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 79(3):629\u2013661. https:\/\/doi.org\/10.1021\/acs.jnatprod.5b01055","journal-title":"J Nat Prod"},{"issue":"Pt 17","key":"1012_CR13","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1242\/jcs.013136","volume":"120","author":"AR Barr","year":"2007","unstructured":"Barr AR, Gergely F (2007) Aurora-A the maker and breaker of spindle poles. J Cell Sci 120(Pt 17):2987\u20132996. https:\/\/doi.org\/10.1242\/jcs.013136","journal-title":"J Cell Sci"},{"issue":"1","key":"1012_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrc1526","volume":"5","author":"T Marumoto","year":"2005","unstructured":"Marumoto T, Zhang D, Saya H (2005) Aurora-A - a guardian of poles. Nat Rev Cancer 5(1):42\u201350. https:\/\/doi.org\/10.1038\/nrc1526","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1012_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ctrv.2007.09.005","volume":"34","author":"G Mountzios","year":"2008","unstructured":"Mountzios G, Terpos E, Dimopoulos MA (2008) Aurora kinases as targets for cancer therapy. Cancer Treat Rev 34(2):175\u2013182. https:\/\/doi.org\/10.1016\/j.ctrv.2007.09.005","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1012_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1677\/erc-07-0213","volume":"15","author":"HH Lee","year":"2008","unstructured":"Lee HH, Zhu Y, Govindasamy KM, Gopalan G (2008) Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells. Endocr Relat Cancer 15(3):765\u2013775. https:\/\/doi.org\/10.1677\/erc-07-0213","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"1012_CR17","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/0008-5472.can-03-2876","volume":"64","author":"R Fonseca","year":"2004","unstructured":"Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD, Stewart AK, Avet-Loiseau H (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64(4):1546\u20131558. https:\/\/doi.org\/10.1158\/0008-5472.can-03-2876","journal-title":"Cancer Res"},{"issue":"11","key":"1012_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1046\/j.1365-2443.2002.00592.x","volume":"7","author":"T Marumoto","year":"2002","unstructured":"Marumoto T, Hirota T, Morisaki T, Kunitoku N, Zhang D, Ichikawa Y, Sasayama T, Kuninaka S, Mimori T, Tamaki N, Kimura M, Okano Y, Saya H (2002) Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 7(11):1173\u20131182. https:\/\/doi.org\/10.1046\/j.1365-2443.2002.00592.x","journal-title":"Genes Cells"},{"issue":"9","key":"1012_CR19","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1182\/blood-2006-07-037671","volume":"109","author":"Y Shi","year":"2007","unstructured":"Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood 109(9):3915\u20133921. https:\/\/doi.org\/10.1182\/blood-2006-07-037671","journal-title":"Blood"},{"issue":"3","key":"1012_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/10428190701824544","volume":"49","author":"R Evans","year":"2008","unstructured":"Evans R, Naber C, Steffler T, Checkland T, Keats J, Maxwell C, Perry T, Chau H, Belch A, Pilarski L, Reiman T (2008) Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 49(3):559\u2013569. https:\/\/doi.org\/10.1080\/10428190701824544","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"1012_CR21","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1182\/blood-2008-12-194290","volume":"114","author":"J Dutta-Simmons","year":"2009","unstructured":"Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC, Carrasco DR (2009) Aurora kinase A is a target of Wnt\/\u03b2-catenin involved in multiple myeloma disease progression. Blood 114(13):2699\u20132708. https:\/\/doi.org\/10.1182\/blood-2008-12-194290","journal-title":"Blood"},{"issue":"2","key":"1012_CR22","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1038\/bcj.2012.47","volume":"3","author":"E Leich","year":"2013","unstructured":"Leich E, Wei\u00dfbach S, Klein HU, Grieb T, Pischimarov J, St\u00fchmer T, Chatterjee M, Steinbrunn T, Langer C, Eilers M, Knop S, Einsele H, Bargou R, Rosenwald A (2013) Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules. Blood Cancer J 3(2):e102\u2013e102. https:\/\/doi.org\/10.1038\/bcj.2012.47","journal-title":"Blood Cancer J"},{"issue":"11","key":"1012_CR23","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","volume":"55","author":"T Sterling","year":"2015","unstructured":"Sterling T, Irwin JJ (2015) ZINC 15-ligand discovery for everyone. J Chem Inf Model 55(11):2324\u20132337. https:\/\/doi.org\/10.1021\/acs.jcim.5b00559","journal-title":"J Chem Inf Model"},{"issue":"1","key":"1012_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28(1):235\u2013242. https:\/\/doi.org\/10.1093\/nar\/28.1.235","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1012_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1021\/jm501326k","volume":"58","author":"JC Carry","year":"2015","unstructured":"Carry JC, Clerc F, Minoux H, Schio L, Mauger J, Nair A, Parmantier E, Le Moigne R, Delorme C, Nicolas JP, Krick A, Ab\u00e9cassis PY, Crocq-Stuerga V, Pouzieux S, Delarbre L, Maignan S, Bertrand T, Bjergarde K, Ma N, Lachaud S, Guizani H, Lebel R, Doerflinger G, Monget S, Perron S, Gasse F, Angouillant-Boniface O, Filoche-Romm\u00e9 B, Murer M, Gontier S, Pr\u00e9vost C, Monteiro ML, Combeau C (2015) SAR156497, an exquisitely selective inhibitor of aurora kinases. J Med Chem 58(1):362\u2013375. https:\/\/doi.org\/10.1021\/jm501326k","journal-title":"J Med Chem"},{"issue":"16","key":"1012_CR26","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256","journal-title":"J Comput Chem"},{"issue":"2","key":"1012_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.phymed.2015.12.011","volume":"23","author":"CF Wu","year":"2016","unstructured":"Wu CF, Seo EJ, Klauck SM, Efferth T (2016) Cryptotanshinone deregulates unfolded protein response and eukaryotic initiation factor signaling in acute lymphoblastic leukemia cells. Phytomedicine 23(2):174\u2013180. https:\/\/doi.org\/10.1016\/j.phymed.2015.12.011","journal-title":"Phytomedicine"},{"issue":"1","key":"1012_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(1):33\u201338. https:\/\/doi.org\/10.1016\/0263-7855(96)00018-5","journal-title":"J Mol Graph"},{"issue":"8","key":"1012_CR29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.phymed.2016.04.007","volume":"23","author":"V Kuete","year":"2016","unstructured":"Kuete V, Mbaveng AT, Nono EC, Simo CC, Zeino M, Nkengfack AE, Efferth T (2016) Cytotoxicity of seven naturally occurring phenolic compounds towards multi-factorial drug-resistant cancer cells. Phytomedicine 23(8):856\u2013863. https:\/\/doi.org\/10.1016\/j.phymed.2016.04.007","journal-title":"Phytomedicine"},{"issue":"17","key":"1012_CR30","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","volume":"267","author":"J O'Brien","year":"2000","unstructured":"O'Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267(17):5421\u20135426. https:\/\/doi.org\/10.1046\/j.1432-1327.2000.01606.x","journal-title":"Eur J Biochem"},{"issue":"4","key":"1012_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1089\/adt.2011.0380","volume":"9","author":"M Jerabek-Willemsen","year":"2011","unstructured":"Jerabek-Willemsen M, Wienken CJ, Braun D, Baaske P, Duhr S (2011) Molecular interaction studies using microscale thermophoresis. Assay Drug Dev Techn 9(4):342\u2013353. https:\/\/doi.org\/10.1089\/adt.2011.0380","journal-title":"Assay Drug Dev Techn"},{"issue":"5","key":"1012_CR32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.apsb.2019.02.001","volume":"9","author":"S Abdelfatah","year":"2019","unstructured":"Abdelfatah S, Berg A, Huang Q, Yang LJ, Hamdoun S, Klinger A, Greten HJ, Fleischer E, Berg T, Wong VK (2019) MCC1019, a selective inhibitor of the polo-box domain of polo-like kinase 1 as novel, potent anticancer candidate. Acta Pharm Sin B 9(5):1021\u20131034. https:\/\/doi.org\/10.1016\/j.apsb.2019.02.001","journal-title":"Acta Pharm Sin B"},{"key":"1012_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.phymed.2017.07.010","volume":"33","author":"V Kuete","year":"2017","unstructured":"Kuete V, Mbaveng AT, Sandjo LP, Zeino M, Efferth T (2017) Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial drug-resistant cancer cells. Phytomedicine 33:62\u201368. https:\/\/doi.org\/10.1016\/j.phymed.2017.07.010","journal-title":"Phytomedicine"},{"issue":"14","key":"1012_CR34","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.3390\/molecules25143224","volume":"25","author":"N \u00d6zenver","year":"2020","unstructured":"\u00d6zenver N, Dawood M, Fleischer E, Klinger A, Efferth T (2020) Chemometric and transcriptomic profiling, microtubule disruption and cell death induction by secalonic acid in tumor cells. Molecules 25(14):3224. https:\/\/doi.org\/10.3390\/molecules25143224","journal-title":"Molecules"},{"issue":"21","key":"1012_CR35","doi-asserted-by":"publisher","first-page":"35103","DOI":"10.18632\/oncotarget.16626","volume":"8","author":"S Hamdoun","year":"2017","unstructured":"Hamdoun S, Efferth T (2017) Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-\u03baB activity. Oncotarget 8(21):35103\u201335115. https:\/\/doi.org\/10.18632\/oncotarget.16626","journal-title":"Oncotarget"},{"key":"1012_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fphar.2019.00542","volume":"10","author":"M Dawood","year":"2019","unstructured":"Dawood M, Ooko E, Efferth T (2019) Collateral sensitivity of parthenolide via NF-\u03baB and HIF-\u03b1 inhibition and epigenetic changes in drug-resistant cancer cell lines. Front Pharmacol 10:542. https:\/\/doi.org\/10.3389\/fphar.2019.00542","journal-title":"Front Pharmacol"},{"issue":"6","key":"1012_CR37","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1021\/ml500409n","volume":"6","author":"TB Sells","year":"2015","unstructured":"Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J, Janowick DA, Kadambi VJ, LeRoy PJ, Stirling M, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Balani SK, Bolen JB, Manfredi MG, Claiborne CF (2015) MLN8054 and Alisertib (MLN8237): discovery of selective oral aurora A inhibitors. ACS Med Chem Lett 6(6):630\u2013634. https:\/\/doi.org\/10.1021\/ml500409n","journal-title":"ACS Med Chem Lett"},{"key":"1012_CR38","doi-asserted-by":"publisher","unstructured":"Pusalkar S, Zhou X, Li Y, Cohen L, Yang JJ, Balani SK, Xia C, Shyu WC, Lu C, Venkatakrishnan K, Chowdhury SK (2020) Biotransformation pathways and metabolite profiles of oral [(14C]-alisertib (MLN8237), an investigational aurora a kinase inhibitor, in patients with advanced solid tumors. Drug Metab Dispos 48(3): 217\u2013229. https:\/\/doi.org\/10.1124\/dmd.119.087338","DOI":"10.1124\/dmd.119.087338"},{"issue":"10","key":"1012_CR39","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1074\/jbc.M115.695874","volume":"291","author":"Y Li","year":"2016","unstructured":"Li Y, Li J, Tian Z, Xu Y, Zhang J, Liu W, Tan H (2016) Coordinative modulation of chlorothricin biosynthesis by binding of the glycosylated intermediates and end product to a responsive regulator ChlF1. J Biol Chem 291(10):5406\u20135417. https:\/\/doi.org\/10.1074\/jbc.M115.695874","journal-title":"J Biol Chem"},{"key":"1012_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fphar.2017.00110","volume":"8","author":"S Hamdoun","year":"2017","unstructured":"Hamdoun S, Jung P, Efferth T (2017) Drug repurposing of the anthelmintic niclosamide to treat multidrug-resistant leukemia. Front Pharmacol 8:110\u2013110. https:\/\/doi.org\/10.3389\/fphar.2017.00110","journal-title":"Front Pharmacol"},{"key":"1012_CR41","doi-asserted-by":"publisher","unstructured":"Efferth T, Oesch F (2019) Repurposing of plant alkaloids for cancer therapy: pharmacology and toxicology. Semin Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2019.12.010","DOI":"10.1016\/j.semcancer.2019.12.010"},{"key":"1012_CR42","doi-asserted-by":"publisher","first-page":"100713","DOI":"10.1016\/j.drup.2020.100713","volume":"52","author":"J Dini\u0107","year":"2020","unstructured":"Dini\u0107 J, Efferth T, Garc\u00eda-Sosa AT, Grahovac J, Padr\u00f3n JM, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I (2020) Repurposing old drugs to fight multidrug resistant cancers. Drug Resist Update 52:100713. https:\/\/doi.org\/10.1016\/j.drup.2020.100713","journal-title":"Drug Resist Update"},{"key":"1012_CR43","doi-asserted-by":"publisher","unstructured":"Kadioglu O, Saeed MEM, Greten HJ, Mayr K, Schrama D, Roos WP, Efferth T (2020) Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.069","DOI":"10.1016\/j.jaad.2020.07.069"},{"key":"1012_CR44","volume-title":"Natural compounds in cancer therapy","author":"J Boik","year":"2001","unstructured":"Boik J (2001) Natural compounds in cancer therapy. Oregon Medical Press, Princeton"},{"issue":"Pt 12","key":"1012_CR45","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1242\/jcs.01108","volume":"117","author":"S Dutertre","year":"2004","unstructured":"Dutertre S, Cazales M, Quaranta M, Froment C, Trabut V, Dozier C, Mirey G, Bouch\u00e9 JP, Theis-Febvre N, Schmitt E, Monsarrat B, Prigent C, Ducommun B (2004) Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci 117(Pt 12):2523\u20132531. https:\/\/doi.org\/10.1242\/jcs.01108","journal-title":"J Cell Sci"},{"issue":"7209","key":"1012_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature07185","volume":"455","author":"L Mac\u016frek","year":"2008","unstructured":"Mac\u016frek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB, Medema RH (2008) Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 455(7209):119\u2013123. https:\/\/doi.org\/10.1038\/nature07185","journal-title":"Nature"},{"key":"1012_CR47","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.2147\/dddt.S75378","volume":"9","author":"JP Li","year":"2015","unstructured":"Li JP, Yang YX, Liu QL, Pan ST, He ZX, Zhang X, Yang T, Chen XW, Wang D, Qiu JX, Zhou SF (2015) The investigational aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2\/M arrest, apoptosis, and autophagy via p38 MAPK and Akt\/mTOR signaling pathways in human breast cancer cells. Drug Des Devel Ther 9:1627\u20131652. https:\/\/doi.org\/10.2147\/dddt.S75378","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"1012_CR48","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2174\/1568009616666160630182344","volume":"17","author":"Q Zhu","year":"2017","unstructured":"Zhu Q, Yu X, Zhou ZW, Zhou C, Chen XW, Zhou SF (2017) Inhibition of aurora A kinase by alisertib induces autophagy and cell cycle arrest and increases chemosensitivity in human hepatocellular carcinoma HepG2 cells. Curr Cancer Drug Targets 17(4):386\u2013401. https:\/\/doi.org\/10.2174\/1568009616666160630182344","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"1012_CR49","first-page":"296","volume":"2","author":"Y Li","year":"2010","unstructured":"Li Y, Zhang ZF, Chen J, Huang D, Ding Y, Tan MH, Qian CN, Resau JH, Kim H, The BT (2010) VX680\/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2(3):296\u2013308","journal-title":"Am J Transl Res"},{"issue":"27","key":"1012_CR50","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1002\/chem.201701208","volume":"23","author":"P Simpson","year":"2017","unstructured":"Simpson P, Casari I, Paternoster S, Skelton B, Falasca M, Massi M (2017) Defining the anti-cancer activity of tricarbonyl rhenium complexes: induction of G2\/M cell cycle arrest and blockade of Aurora-A kinase phosphorylation. Chem Eur 23(27):6518\u20136521. https:\/\/doi.org\/10.1002\/chem.201701208","journal-title":"Chem Eur"},{"issue":"3","key":"1012_CR51","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1083\/jcb.200108135","volume":"156","author":"R Giet","year":"2002","unstructured":"Giet R, McLean D, Descamps S, Lee M, Raff J, Prigent C, Glover D (2002) Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J Cell Biol 156(3):436\u2013451. https:\/\/doi.org\/10.1083\/jcb.200108135","journal-title":"J Cell Biol"},{"issue":"1","key":"1012_CR52","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/s41467-018-04089-9","volume":"9","author":"G Eot-Houllier","year":"2018","unstructured":"Eot-Houllier G, Magnaghi-Jaulin L, Fulcrand G, Moyroud FX, Monier S, Jaulin C (2018) Aurora A-dependent CENP-A phosphorylation at inner centromeres protects bioriented chromosomes against cohesion fatigue. Nat Commun 9(1):1888. https:\/\/doi.org\/10.1038\/s41467-018-04089-9","journal-title":"Nat Commun"},{"issue":"1","key":"1012_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1476-4598-10-131","volume":"10","author":"IA Asteriti","year":"2011","unstructured":"Asteriti IA, Giubettini M, Lavia P, Guarguaglini G (2011) Aurora-A inactivation causes mitotic spindle pole fragmentation by unbalancing microtubule-generated forces. Mol Cancer 10(1):131. https:\/\/doi.org\/10.1186\/1476-4598-10-131","journal-title":"Mol Cancer"},{"issue":"6","key":"1012_CR54","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.devcel.2010.11.011","volume":"19","author":"ME Tanenbaum","year":"2010","unstructured":"Tanenbaum ME, Medema RH (2010) Mechanisms of centrosome separation and bipolar spindle assembly. Dev Cell 19(6):797\u2013806. https:\/\/doi.org\/10.1016\/j.devcel.2010.11.011","journal-title":"Dev Cell"},{"issue":"17","key":"1012_CR55","doi-asserted-by":"publisher","first-page":"R749","DOI":"10.1016\/j.cub.2009.07.028","volume":"19","author":"S Dumont","year":"2009","unstructured":"Dumont S, Mitchison TJ (2009) Force and length in the mitotic spindle. Curr Biol 19(17):R749\u2013R761. https:\/\/doi.org\/10.1016\/j.cub.2009.07.028","journal-title":"Curr Biol"},{"issue":"7","key":"1012_CR56","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1083\/jcb.200504097","volume":"170","author":"TP Barros","year":"2005","unstructured":"Barros TP, Kinoshita K, Hyman AA, Raff JW (2005) Aurora A activates D-TACC-Msps complexes exclusively at centrosomes to stabilize centrosomal microtubules. J Cell Biol 170(7):1039\u20131046. https:\/\/doi.org\/10.1083\/jcb.200504097","journal-title":"J Cell Biol"},{"issue":"51","key":"1012_CR57","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1038\/onc.2008.252","volume":"27","author":"M De Luca","year":"2008","unstructured":"De Luca M, Brunetto L, Asteriti IA, Giubettini M, Lavia P, Guarguaglini G (2008) Aurora-A and ch-TOG act in a common pathway in control of spindle pole integrity. Oncogene 27(51):6539\u20136549. https:\/\/doi.org\/10.1038\/onc.2008.252","journal-title":"Oncogene"},{"issue":"5","key":"1012_CR58","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1095\/biolreprod.103.025155","volume":"70","author":"LJ Yao","year":"2004","unstructured":"Yao LJ, Zhong ZS, Zhang LS, Chen DY, Schatten H, Sun QY (2004) Aurora-A is a critical regulator of microtubule assembly and nuclear activity in mouse oocytes, fertilized eggs, and early embryos1. Biol Reprod 70(5):1392\u20131399. https:\/\/doi.org\/10.1095\/biolreprod.103.025155","journal-title":"Biol Reprod"},{"issue":"1","key":"1012_CR59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/biom9010028","volume":"9","author":"L Magnaghi-Jaulin","year":"2019","unstructured":"Magnaghi-Jaulin L, Eot-Houllier G, Gallaud E, Giet R (2019) Aurora A protein kinase: to the centrosome and beyond. Biomolecules 9(1):28. https:\/\/doi.org\/10.3390\/biom9010028","journal-title":"Biomolecules"},{"issue":"5","key":"1012_CR60","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/s0092-8674(03)00642-1","volume":"114","author":"T Hirota","year":"2003","unstructured":"Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K, Saya H (2003) Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114(5):585\u2013598. https:\/\/doi.org\/10.1016\/s0092-8674(03)00642-1","journal-title":"Cell"},{"issue":"11","key":"1012_CR61","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1182\/blood.V108.11.847.847","volume":"108","author":"T Reiman","year":"2006","unstructured":"Reiman T, Evans RP, Naber C, Steffler T, Keats JJ, Perry T, Maxwell CA, Chau H, Belch AR, Pilarski LM (2006) Aurora kinases as therapeutic targets in multiple myeloma. Blood 108(11):847\u2013847. https:\/\/doi.org\/10.1182\/blood.V108.11.847.847","journal-title":"Blood"},{"key":"1012_CR62","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fonc.2015.00295","volume":"5","author":"AB D'Assoro","year":"2016","unstructured":"D'Assoro AB, Haddad T, Galanis E (2016) Aurora-A kinase as a promising therapeutic target in cancer. Front Oncol 5:295\u2013295. https:\/\/doi.org\/10.3389\/fonc.2015.00295","journal-title":"Front Oncol"},{"issue":"2","key":"1012_CR63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/2496","volume":"20","author":"H Zhou","year":"1998","unstructured":"Zhou H, Kuang J, Zhong L, Kuo WL, Gray J, Sahin A, Brinkley B, Sen S (1998) Tumour amplified kinase STK15\/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20(2):189\u2013193. https:\/\/doi.org\/10.1038\/2496","journal-title":"Nat Genet"},{"key":"1012_CR64","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/ijc.22154","volume":"119","author":"L He","year":"2006","unstructured":"He L, Kruk P, Nicosia S, Cheng J (2006) Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 119:2304\u20132312. https:\/\/doi.org\/10.1002\/ijc.22154","journal-title":"Int J Cancer"},{"issue":"4","key":"1012_CR65","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3892\/mmr.2011.494","volume":"4","author":"Y Li","year":"2011","unstructured":"Li Y, Tang K, Zhang H, Zhang Y, Zhou W, Chen X (2011) Function of Aurora kinase A in taxol-resistant breast cancer and its correlation with P-gp. Mol Med Rep 4(4):739\u2013746. https:\/\/doi.org\/10.3892\/mmr.2011.494","journal-title":"Mol Med Rep"},{"issue":"4","key":"1012_CR66","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3892\/ol.2011.295","volume":"2","author":"T Terakawa","year":"2011","unstructured":"Terakawa T, Miyake H, Kumano M, Fujisawa M (2011) Growth inhibition and enhanced chemosensitivity induced by down-regulation of Aurora-A in human renal cell carcinoma Caki-2 cells using short hairpin RNA. Oncol Lett 2(4):713\u2013717. https:\/\/doi.org\/10.3892\/ol.2011.295","journal-title":"Oncol Lett"}],"updated-by":[{"DOI":"10.1007\/s10637-021-01193-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000}}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01012-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-01012-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01012-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:56:56Z","timestamp":1678510616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-01012-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1012"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-01012-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10637-021-01193-4","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"21 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10637-021-01193-4","URL":"https:\/\/doi.org\/10.1007\/s10637-021-01193-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"EF and AK are employees of MicroCombiChem, Wiesbaden, Germany. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. \/All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. \/All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required. Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}